Evaluation of infliximab/tocilizumab versus tocilizumab among COVID-19 patients with cytokine storm syndrome

Coronavirus Disease 2019 (COVID-19) continues to spread rapidly. Monoclonal antibodies as well as anti-tumor necrosis factor are considered promising treatments for COVID-19. A prospective cohort study in which patients are divided into three groups. Group 1: moderate and severe COVID-19 patients re...

Descripción completa

Detalles Bibliográficos
Autores principales: Sarhan, Neven Mohamed, Warda, Ahmed Essam Abou, Ibrahim, Haytham Soliman Ghareeb, Schaalan, Mona Farag, Fathy, Shaimaa Mohamed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116445/
https://www.ncbi.nlm.nih.gov/pubmed/37081046
http://dx.doi.org/10.1038/s41598-023-33484-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10116445/
https://www.ncbi.nlm.nih.gov/pubmed/37081046
http://dx.doi.org/10.1038/s41598-023-33484-6

Ejemplares similares